Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: Relation to adverse tumor phenotype and predisposing mutation

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 65-78

  Kiss, Nimrod B ^a   Muth, Andreas ^a   Andreasson, Adam ^a   Juhlin, C Christofer ^a,c   Geli, Janos ^a   Bäckdahl, Martin ^a   Höög, Anders ^c   Wängberg, Bo ^b   Nilsson, Ola ^b   Ahlman, Hakan ^b   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adrenal medulla; Endocrine therapy; Gene regulation; Metastasis; Molecular genetics

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MUTATION; PARAGANGLIOMA; PRIMARY TUMOR; PROTEIN METHYLATION; PYROSEQUENCING; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MUTATION; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; SUCCINATE DEHYDROGENASE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84874088648     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0267     Document Type: Article

References (38)

1. Agger K, Christensen J, Cloos PAC & Helin K 2008 The emerging functions of histone demethylases. Current Opinion in Genetics & Development 18 159-168. (doi:10.1016/j.gde.2007.12.003)
2. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, MyssiorekD, Bosch A, Mey A, Taschner PEM, RubinsteinWS & Myers EN 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 848. (doi:10.1126/science.287.5454.848)
3. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ & Robinson BG 2003 Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22 1358-1364. (doi:10.1038/sj.onc.1206300)
4. Boedeker C 2011 Paragangliomas and paraganglioma syndromes. Laryngo-Rhino-Otologie 90 S56-S82. (doi:10.1055/s-0030-1270447)
5. Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P & Tzagoloff A 2010 SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics 19 3011. (doi:10.1093/hmg/ddq206)
6. Cascon A, Ruiz-Llorente S, Fraga M, Leton R, Telleria D, Sastre J, Diez JJ, Diaz-Guerra GM, Perez JAD & Benitez J 2004 Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics 41 e30-e30. (doi:10.1136/jmg.2003.012658)
7. Castellano M, Mori L, Giacche M, Agliozzo E, Tosini R, Panarotto A, Cappelli C, Mulatero P, Cumetti D & Veglio F 2006 Genetic mutation screening in an Italian cohort of nonsyndromic pheochromocytoma/ paraganglioma patients. Annals of the New York Academy of Sciences 1073 156-165. (doi:10.1196/annals. 1353.016)
8. Cervera AM, Apostolova N, Crespo FL, Mata M & McCreath KJ 2008 Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Research 68 4058. (doi:10.1158/0008-5472. CAN-07-5580)
9. Cervera AM, Bayley JP, Devilee P & McCreath KJ 2009 Inhibition of succinate dehydrogenase dysregulates histone modifications in mammalian cells. Molecular Cancer 8 89. (doi:10.1186/1476-4598-8-89)
10. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-Garci'a LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D & Pita G 2011 Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 43 663-667. (doi:10.1038/ng.861)
11. DeLellis RA 2004 Tumors of the adrenal gland. In World Health Organization Classification of Tumors. Pathology & Genetics, pp136-166. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon, France: IARC Press.
12. Edström Elder E, Hjelm Skog AL, Höög A & Hamberger B 2003 The management of benign and malignant pheochromocytoma and abdominal paraganglioma. European Journal of Surgical Oncology 29 278-283. (doi:10.1053/ejso.2002.1413)
13. Elder EE, Elder G & Larsson C 2005 Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Journal of Surgical Oncology 89 193-201. (doi:10.1002/jso.20177)
14. Geli J, Kiss N, Lanner F, Foukakis T, Natalishvili N, Larsson O, Kogner P, Höög A, Clark GJ & Ekström TJ 2007 The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocrine-Related Cancer 14 125-134. (doi:10.1677/ERC-06-0031)
15. Geli J, Kiss N, Karimi M, Lee JJ, Bäckdahl M, Ekström TJ & Larsson C 2008 Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association tomalignant behavior. Clinical Cancer Research 14 2551-2559. (doi:10.1158/1078-0432.CCR-07-1867)
16. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD & Bentz BG 2009 SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325 1139-1142. (doi:10.1126/science.1175689)
17. Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Oden A, StenströmG, Hansson G, Stenquist O, Wängberg B & Tisell LE 2005 Long-term outcome of a large series of patients surgically treated for pheochromocytoma. Journal of Internal Medicine 258 55-66. (doi:10.1111/j.1365- 2796.2005.01504.x)
18. Kiss N, Geli J, Lundberg F, Avci C, Velazquez-Fernandez D, Hashemi J, Weber G, Höög A, Ekström T & Bäckdahl M 2008 Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Endocrine-Related Cancer 15 609-621. (doi:10.1677/ERC-07-0285)
19. Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C & Geli J 2012 Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Medical Genetics 13 83. (doi:10.1186/1471-2350-13-83)
20. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD & Kaelin WG, Jr 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 155-167. (doi:10.1016/ j.ccr.2005.06.015)
21. Lin Y, Diccianni M, Kim Y, Lin H, Lee C, Lin R, Joo S, Li J, Chuang T & Yang A 2007 Human p16g, a novel transcriptional variant of p16INK4A, coexpresses with p16INK4A in cancer cells and inhibits cell-cycle progression. Oncogene 26 7017-7027. (doi:10.1038/sj.onc. 1210507)
22. Margetts C, Astuti D, Gentle D, Cooper W, Cascon A, Catchpoole D, Robledo M, Neumann H, Latif F & Maher E 2005 Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocrine-Related Cancer 12 161-172. (doi:10.1677/erc.1.00865)
23. Muscarella P, Bloomston M, Brewer AR, Mahajan A, Frankel WL, Ellison EC, Farrar WB, Weghorst CM & Li J 2008 Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens. Gene Expression 14 207-216. (doi:10.3727/105221608786883825)
24. Muth A, Abel F, Jansson S, Nilsson O, Ahlman H & Wängberg B 2012 Prevalence of germline mutations in patients with pheochromocytoma or abdominal paraganglioma and sporadic presentation: a populationbased study in western Sweden. World Journal of Surgery 36 1389-1394. (doi:10.1007/s00268-012-1430-6)
25. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EMCA, Sleddens HF, Derkx P, Rivière J & Dannenberg H 2009 An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology 10 764-771. (doi:10.1016/S1470-2045(09)70164-0)
26. Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C & Zerres K 2002 Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466. (doi:10.1056/NEJMoa020152)
27. Pollard P, Briere J, Alam N, Barwell J, Barclay E, Wortham N, Hunt T, Mitchell M, Olpin S & Moat SJ 2005 Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14 2231. (doi:10.1093/hmg/ddi227)
28. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N & Schiavi F 2010 Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 42 229-233. (doi:10.1038/ng.533)
29. Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, Cole TR, Armstrong R, Kumar V & Morrison PJ 2010 Tumor risks and genotype- phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation 31 41-51. (doi:10.1002/ humu.21136)
30. Sandgren J, Andersson R, Rada-Iglesias A, Enroth S, Akerström G, Dumanski JP, Komorowski J, Westin G & Wadelius C 2010a Integrative epigenomic and genomic analysis of malignant pheochromocytoma. Experimental & Molecular Medicine 42 484. (doi:10.3858/emm.2010.42. 7.050)
31. Sandgren J, de Stahl TD, Andersson R, Menzel U, Piotrowski A, Nord H, Bäckdahl M, Kiss NB, Brauckhoff M & Komorowski J 2010b Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis. Endocrine-Related Cancer 17 561-579. (doi:10.1677/ERC-09-0310)
32. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB & Gottlieb E 2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-[a] prolyl hydroxylase. Cancer Cell 7 77-85. (doi:10.1016/j.ccr. 2004.11.022)
33. Smith EH, Janknecht R & Maher LJ 2007 Succinate inhibition of a-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Human Molecular Genetics 16 3136. (doi:10.1093/hmg/ ddm275)
34. Tischler AS 2008 Pheochromocytoma and extra-adrenal paraganglioma: updates. Archives of Pathology & Laboratory Medicine 132 1272-1284. (doi:10.1043/1543-2165(2008)132[1272:PAEPU]2.0.CO;2)
35. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB & Issa JPJ 1999 CpG island methylator phenotype in colorectal cancer. PNAS 96 8681. (doi:10.1073/pnas.96.15.8681)
36. Wängberg B, Muth A, Khorram-Manesh A, Jansson S, Nilsson O, Forssell-Aronsson E, Tisell L & Ahlman H 2006 Malignant pheochromocytoma in a population-based study. Annals of the New York Academy of Sciences 1073 512-516. (doi:10.1196/annals. 1353.054)
37. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E & Ricketts CJ 2010 Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. Journal of the American Medical Association 304 2611-2619. (doi:10.1001/jama.2010.1830)
38. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L & DePinho RA 2002 Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. PNAS 99 1455. (doi:10.1073/pnas. 022632099)